litlas
Log inCreate account

Philippe L. Bédard

Active 2009–2026

Also published as
Philippe L. Bedard
155
Papers
18,618
Citations
66
h-index
136
i10-index

Citations

Citations per year for Philippe L. Bédard1992: 1 citations2003: 1 citations2004: 1 citations2010: 14 citations2011: 10 citations2012: 37 citations2013: 64 citations2014: 88 citations2015: 101 citations2016: 131 citations2017: 137 citations2018: 148 citations2019: 615 citations2020: 908 citations2021: 1,096 citations2022: 1,042 citations2023: 876 citations2024: 1,271 citations2025: 729 citations2026: 23 citations1993–2002: no citations, so these years are not shown2005–2009: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,886 citing papers, 24% of this breakdownChina: 1,318 citing papers, 11% of this breakdownItaly: 800 citing papers, 6.6% of this breakdownUnited Kingdom: 721 citing papers, 6% of this breakdownCanada: 582 citing papers, 4.8% of this breakdownGermany: 579 citing papers, 4.8% of this breakdownFrance: 519 citing papers, 4.3% of this breakdownSpain: 457 citing papers, 3.8% of this breakdownSwitzerland: 310 citing papers, 2.6% of this breakdownAustralia: 307 citing papers, 2.6% of this breakdownNetherlands: 306 citing papers, 2.5% of this breakdownJapan: 289 citing papers, 2.4% of this breakdown
0%24%Other 24.6%

Institutions

Fields

  • Medicine51.1%
  • Biochemistry, Genetics and Molecular Biology40.3%
  • Immunology and Microbiology2.7%
  • Computer Science1.4%
  • Engineering0.9%
  • Materials Science0.6%
  • Other3%

Topics

  • Cancer Genomics and Diagnostics8.2%
  • Cancer Immunotherapy and Biomarkers5.7%
  • Lung Cancer Treatments and Mutations3.4%
  • HER2/EGFR in Cancer Research2.6%
  • Advanced Breast Cancer Therapies2.2%
  • Cancer Cells and Metastasis2.2%
  • Other75.7%

Coauthors

All papers

Open in search
  1. AACR Project GENIE: Powering Precision Medicine through an International Consortium

    Authors: Fabrice André, Mónica Arnedos, Alexander S. Baras, José Baselga, Philippe L. Bédard, Michael F. Berger, Mariska Bierkens, Fabien Calvo, Ethan Cerami, Debyani Chakravarty, Kristen K. Dang, Nancy E. Davidson, Catherine Del Vecchio Fitz, Semih Doğan, Raymond N. DuBois, Matthew D. Ducar, P. Andrew Futreal, Jianjiong Gao, Francisco Moacir Pinheiro Garcia, Stuart M. Gardos, Christopher D. Gocke, Benjamin Groß, Justin Guinney, Zachary Heins, Stephanie Hintzen, Hugo M. Horlings, Jan Hudeček, David M. Hyman, Suzanne Kamel‐Reid, Cyriac Kandoth, Walter Kinyua, Priti Kumari, Ritika Kundra, Marc Ladanyi, Céline Lefèbvre, Michele L. Lenoue-Newton, Eva M. Lepisto, Mia Levy, Neal I. Lindeman, James Lindsay, David Liu, Zhibin Lu, Laura E. MacConaill, Ian Maurer, David S. Maxwell, Gerrit A. Meijer, Funda Meric‐Bernstam, Christine Micheel, Clinton Miller, Gordon B. Mills, Nathanael D. Moore, Petra M. Nederlof, Larsson Omberg, John A. Orechia, Ben Ho Park, Trevor J. Pugh, Brendan Reardon, Barrett J. Rollins, Mark J. Routbort, Charles L. Sawyers, Deborah Schrag, Nikolaus Schultz, Kenna Shaw, Priyanka Shivdasani, Lillian L. Siu, David B. Solit, Gabe S. Sonke, Jean Charles Soria, Parin Sripakdeevong, Natalie Stickle, Thomas Stricker, Shawn M. Sweeney, Barry S. Taylor, Jelle J. ten Hoeve, Stacy B. Thomas, Eliezer M. Van Allen, Laura van ‘t Veer, Tony van de Velde, Harm van Tinteren, Victor E. Velculescu, Carl Virtanen, Emile E. Voest, Lucy Lu Wang, Chetna Wathoo, Stuart Watt, Celeste Yu, Thomas Yu, Emily Yu, Ahmet Zehir, Hongxin Zhang - Cancer Discovery 2017 cited by 2,004

  2. Sensitive tumour detection and classification using plasma cell-free DNA methylomes

    Authors: Shu Yi Shen, Rajat Singhania, Gordon Fehringer, Ankur Chakravarthy, Michael H. A. Roehrl, Dianne Chadwick, Philip C. Zuzarte, Ayelet Borgida, Ting Ting Wang, Tiantian Li, Olena Kis, Zhen Zhao, Anna Spreafico, Tiago da Silva Medina, Yadon Wang, David Roulois, Ilias Ettayebi, Zhuo Chen, Signy Chow, Tracy Murphy, Andrea Arruda, Grainne M. O’Kane, Jessica Liu, Mark Mansour, John D. McPherson, Catherine O′Brien, Natasha B. Leighl, Philippe L. Bédard, Neil Fleshner, Geoffrey Liu, Mark D. Minden, Steven Gallinger, Anna Goldenberg, Trevor J. Pugh, Michael M. Hoffman, Scott V. Bratman, Rayjean J. Hung, Daniel D. De Carvalho - Nature 2018 cited by 1,040

  3. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

    Authors: Joaquı́n Mateo, Debyani Chakravarty, Rodrigo Dienstmann, S. Jezdic, Abel González-Pérez, Núria López-Bigas, Charlotte K.Y. Ng, Philippe L. Bédard, Giampaolo Tortora, J.-Y. Douillard, Eliezer M. Van Allen, Nikolaus Schultz, Charles Swanton, F. André, Lajos Pusztai - Annals of Oncology 2018 cited by 787

  4. Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

    Authors: Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach, Toshihiko Doi, David Tai, Patrick M. Forde, John Sarantopoulos, Philippe L. Bédard, Chia‐Chi Lin, F. Stephen Hodi, Sofie Wilgenhof, Armando Santoro, Catherine Sabatos-Peyton, Tyler A. Longmire, Alexandros Xyrafas, Haiying Sun, Sabine Gutzwiller, Luigi Manenti, Aung Naing - Clinical Cancer Research 2021 cited by 348

  5. Small molecules, big impact: 20 years of targeted therapy in oncology

    Authors: Philippe L. Bédard, David M. Hyman, Matthew S. Davids, Lillian L. Siu - The Lancet 2020 cited by 602

  6. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab

    Authors: Scott V. Bratman, S.Y. Cindy Yang, Marco Iafolla, Zhihui Liu, Aaron R. Hansen, Philippe L. Bédard, Stéphanie Lheureux, Anna Spreafico, Albiruni Abdul Razak, Svetlana Shchegrova, Maggie C. Louie, Paul R. Billings, Bernhard Zimmermann, Himanshu Sethi, Alexey Aleshin, Dax Torti, Kayla Marsh, Jenna Eagles, Iulia Cirlan, Youstina Hanna, Derek Clouthier, Scott Lien, Pamela S. Ohashi, Wei Xu, Lillian L. Siu, Trevor J. Pugh - Nature Cancer 2020 cited by 480

  7. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

    Authors: Nancy U. Lin, Virginia F. Borges, Carey K. Anders, Rashmi K. Murthy, Elisavet Paplomata, Erika Hamilton, Sara A. Hurvitz, Sherene Loi, Alicia Okines, Vandana G. Abramson, Philippe L. Bédard, Mafalda Oliveira, Volkmar Müller, Amelia Zelnak, Michael P. DiGiovanna, Thomas Bachelot, A. Jo Chien, Ruth O’Regan, Andrew Wardley, Alison Conlin, David Cameron, Lisa A. Carey, Giuseppe Curigliano, Karen A. Gelmon, Sibylle Loibl, JoAl Mayor, Suzanne McGoldrick, Xuebei An, Eric P. Winer - Journal of Clinical Oncology 2020 cited by 549

  8. Tumour heterogeneity in the clinic

    Authors: Philippe L. Bédard, Aaron R. Hansen, Mark J. Ratain, Lillian L. Siu - Nature 2013 cited by 1,230

  9. Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases

    Authors: Nancy U. Lin, Rashmi K. Murthy, Vandana G. Abramson, Carey K. Anders, Thomas Bachelot, Philippe L. Bédard, Virginia F. Borges, David Cameron, Lisa A. Carey, A. Jo Chien, Giuseppe Curigliano, Michael P. DiGiovanna, Karen A. Gelmon, Gabriel N. Hortobágyi, Sara A. Hurvitz, Ian E. Krop, Sherene Loi, Sibylle Loibl, Volkmar Müller, Mafalda Oliveira, Elisavet Paplomata, Mark D. Pegram, Dennis J. Slamon, Amelia Zelnak, Jorge Ramos, Wentao Feng, Eric P. Winer - JAMA Oncology 2022 cited by 197

  10. Novel patterns of response under immunotherapy

    Authors: Édith Borcoman, Yada Kanjanapan, Stéphane Champiat, Shotaro Kato, Vincent Servois, Razelle Kurzrock, Sanjay Goel, Philippe L. Bédard, Christophe Le Tourneau - Annals of Oncology 2019 cited by 511

  11. A Phase 1 Study of SLC-0111, a Novel Inhibitor of Carbonic Anhydrase IX, in Patients With Advanced Solid Tumors

    Authors: Paul C. McDonald, Stephen Chia, Philippe L. Bédard, Quincy Chu, Michael P. A. Lyle, Liren Tang, Madhu Singh, Zaihui Zhang, Claudiu T. Supuran, Daniel J. Renouf, Shoukat Dedhar - American Journal of Clinical Oncology 2020 cited by 250

  12. Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies

    Authors: John Hilton, Karen A. Gelmon, Philippe L. Bédard, Dongsheng Tu, Hong Xu, Anna V. Tinker, Rachel Goodwin, Scott A. Laurie, Derek J. Jonker, Aaron R. Hansen, Zachary Veitch, Daniel J. Renouf, Linda Hagerman, Hongbo Lui, Bingshu E. Chen, Deb Kellar, Irene Li, Sung‐Eun Lee, Takako Kono, Brian Yu Chieh Cheng, Damian Yap, Daniel Lai, Sean Beatty, John Soong, Kathleen I. Pritchard, Isabel Soria‐Bretones, Eric X. Chen, Harriet Feilotter, Moira Rushton, Lesley Seymour, Samuel Aparício, David W. Cescon - Nature Communications 2022 cited by 145

  13. Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

    Authors: Hope S. Rugo, Jean‐Pierre Delord, Seock‐Ah Im, Patrick A. Ott, Sarina A. Piha‐Paul, Philippe L. Bédard, Jasgit C. Sachdev, Christophe Le Tourneau, Emilie M.J. van Brummelen, Andréa Varga, Roberto Salgado, Sherene Loi, Sanatan Saraf, Dina Pietrangelo, Vassiliki Karantza, Antoinette R. Tan - Clinical Cancer Research 2018 cited by 387

  14. Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative

    Authors: Philippe Aftimos, Mafalda Oliveira, Alexandre Irrthum, Debora Fumagalli, Christos Sotiriou, Einav Nili Gal‐Yam, Mark E. Robson, Justin Ndozeng, Angelo Di Leo, Eva Ciruelos, Evandro de Azambuja, Giuseppe Viale, Elsemieke D. Scheepers, Giuseppe Curigliano, Judith M. Bliss, Jorge S. Reis‐Filho, Marco Colleoni, Marija Balić, Fátima Cardoso, Joan Albanell, Caroline Duhem, Sandrine Marréaud, Dario Romagnoli, Beatriz Rojas, Andrea Gombos, Hans Wildiers, Ángel Guerrero‐Zotano, Peter S Hall, Andrea Bonetti, Karolina Larsson, Martina Degiorgis, Silvia Khodaverdi, Richard Greil, Ásgerður Sverrisdóttir, Marta Paoli, Ethel Seyll, Sibylle Loibl, Barbro Linderholm, Gabriele Zoppoli, Nancy E. Davidson, Oskar T. Johannsson, Philippe L. Bédard, Sherene Loi, Susan Knox, David Cameron, Nadia Harbeck, Maite Lasa Montoya, Mariana Brandão, Andrea Vingiani, Carmela Caballero, Florentine Hilbers, Lucy Yates, Matteo Benelli, David Venet, Martine Piccart - Cancer Discovery 2021 cited by 177

  15. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors

    Authors: Tae Won Kim, Philippe L. Bédard, Patricia LoRusso, Michael S. Gordon, Johanna C. Bendell, Do‐Youn Oh, Myung‐Ju Ahn, Elena Garralda, Sandra P. D’Angelo, Jayesh Desai, F. Stephen Hodi, Zev A. Wainberg, Jean‐Pierre Delord, Phillippe A. Cassier, Andrés Cervantes, Marta Gil-Martín, Benjamin Wu, Namrata S. Patil, Yanling Jin, Tien Hoang, Diana Mendus, Xiaohui Wen, Raymond D. Meng, Byoung Chul Cho - JAMA Oncology 2023 cited by 63

  16. Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Cancer: A Population-Based Study

    Authors: Lawson Eng, Rinku Sutradhar, Yue Niu, Ning Liu, Ying Liu, Yosuf Kaliwal, Melanie Powis, Geoffrey Liu, Jeffrey Peppercorn, Philippe L. Bédard, Monika K. Krzyzanowska - Journal of Clinical Oncology 2023 cited by 102

  17. OncoTree: A Cancer Classification System for Precision Oncology

    Authors: Ritika Kundra, Hongxin Zhang, Robert P. Sheridan, S. Joseph Sirintrapun, Avery Wang, Angelica Ochoa, Manda Wilson, Benjamin Groß, Yichao Sun, Ramyasree Madupuri, Baby A. Satravada, Dalicia N. Reales, Efsevia Vakiani, Hikmat Al‐Ahmadie, Ahmet Doǧan, Maria E. Arcila, Ahmet Zehir, Steven B. Maron, Michael F. Berger, Cristina Viaplana, Katherine A. Janeway, Matthew D. Ducar, Lynette M. Sholl, Snjezana Doğan, Philippe L. Bédard, Lea F. Surrey, Iker Huerga Sanchez, Aijaz Syed, Anoop Balakrishnan Rema, Debyani Chakravarty, Sarah P. Suehnholz, Moriah H. Nissan, Gopa Iyer, Rajmohan Murali, Nancy Bouvier, Robert A. Soslow, David M. Hyman, Anas Younes, Andrew M. Intlekofer, James J. Harding, Richard D. Carvajal, Paul Sabbatini, Ghassan K. Abou‐Alfa, Luc G.T. Morris, Yelena Y. Janjigian, Meighan M. Gallagher, Tara A. Soumerai, Ingo K. Mellinghoff, A. Ari Hakimi, Matthew G. Fury, Jason T. Huse, Aditya Bagrodia, Meera Hameed, Stacy B. Thomas, Stuart M. Gardos, Ethan Cerami, Tali Mazor, Priti Kumari, Pichai Raman, Priyanka Shivdasani, Suzanne P. MacFarland, Scott Newman, Angela J. Waanders, Jianjiong Gao, David B. Solit, Nikolaus Schultz - JCO Clinical Cancer Informatics 2021 cited by 150

  18. A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors

    Authors: Philippe L. Bédard, Josep Tabernero, Filip Jankú, Zev A. Wainberg, Luis Paz‐Ares, Johan Vansteenkiste, Eric Van Cutsem, José Manuel Pérez-García, Anastasios Stathis, Carolyn D. Britten, Ngocdiep T. Le, Kirsten Carter, David Demanse, Dénes Csonka, Malte Peters, Angela Zubel, Heidi Nauwelaerts, Cristiana Sessa - Clinical Cancer Research 2014 cited by 326

  19. A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA -Mutated Breast and Gynecologic Cancers

    Authors: Udai Banerji, Emma Dean, José Alejandro Pérez Fidalgo, Gerald Batist, Philippe L. Bédard, Benoît You, Shannon N. Westin, Peter Kabos, Michelle D. Garrett, Mathew Tall, Helen Ambrose, J. Carl Barrett, T. Hedley Carr, S.Y. Amy Cheung, Claire Corcoran, Marie Cullberg, Barry R. Davies, Elza C. de Bruin, Paul Elvin, Andrew Foxley, Peter Lawrence, Justin P.O. Lindemann, Rhiannon Maudsley, Martin Pass, Vicky Rowlands, Paul Rugman, Gaia Schiavon, James Yates, Jan H.M. Schellens - Clinical Cancer Research 2017 cited by 146

  20. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study

    Authors: Anas Gazzah, Philippe L. Bédard, Cinta Hierro, Yubin Kang, Albiruni Abdul Razak, M.H. Ryu, B. Demers, Nathalie Fagniez, Christophe Henry, Marie Hospitel, J.C. Soria, Josep Tabernero - Annals of Oncology 2022 cited by 81

  21. Leveraging big data of immune checkpoint blockade response identifies novel potential targets

    Authors: Yacine Barèche, Deirdre Kelly, Farnoosh Abbas‐Aghababazadeh, Masahiro Nakano, Parinaz Nasr Esfahani, Douglas Tkachuk, Helai P. Mohammad, Robert Samstein, Chung‐Han Lee, Luc G.T. Morris, Philippe L. Bédard, Benjamin Haibe‐Kains, John Stagg - Annals of Oncology 2022 cited by 81

  22. AKT Inhibition in Solid Tumors With AKT1 Mutations

    Authors: David M. Hyman, Lillian M. Smyth, Mark T.A. Donoghue, Shannon N. Westin, Philippe L. Bédard, Emma Dean, Hideaki Bando, Anthony B. El-Khoueiry, José Alejandro Pérez Fidalgo, Alain C. Mita, Jan H.M. Schellens, Matthew T. Chang, Jonathan Reichel, Nancy Bouvier, S. Duygu Selçuklu, Tara E. Soumerai, Jean Torrisi, Joseph P. Erinjeri, Helen Ambrose, J. Carl Barrett, Brian Dougherty, Andrew Foxley, Justin P.O. Lindemann, Robert McEwen, Martin Pass, Gaia Schiavon, Michael F. Berger, Sarat Chandarlapaty, David B. Solit, Udai Banerji, José Baselga, Barry S. Taylor - Journal of Clinical Oncology 2017 cited by 325

  23. Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity

    Authors: S.Y. Cindy Yang, Scott Lien, Ben X. Wang, Derek Clouthier, Youstina Hanna, Iulia Cirlan, Kelsey Zhu, Jeffrey P. Bruce, Samah El Ghamrasni, Marco Iafolla, Marc Oliva, Aaron R. Hansen, Anna Spreafico, Philippe L. Bédard, Stéphanie Lheureux, Albiruni Abdul Razak, Vanessa Speers, Hal K. Berman, Alexey Aleshin, Benjamin Haibe‐Kains, David G. Brooks, Tracy L. McGaha, Marcus O. Butler, Scott V. Bratman, Pamela S. Ohashi, Lillian L. Siu, Trevor J. Pugh - Nature Communications 2021 cited by 128

  24. A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors

    Authors: Suzanne F. Jones, Lillian L. Siu, Johanna C. Bendell, James M. Cleary, Albiruni R. Abdul Razak, Jeffrey R. Infante, Shuchi S. Pandya, Philippe L. Bédard, Kristen J. Pierce, Brett E. Houk, W. Gregory Roberts, S. Martin Shreeve, Geoffrey I. Shapiro - Investigational New Drugs 2015 cited by 170